[{"id":"6193f02a-522d-4868-bdfe-0cbcfe1502ee","acronym":"SQZ-PBMC-HPV-101","url":"https://clinicaltrials.gov/study/NCT04084951","created_at":"2021-06-30T14:53:47.022Z","updated_at":"2024-07-02T16:35:50.584Z","phase":"Phase 1","brief_title":"Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT04084951 - SQZ-PBMC-HPV-101","lead_sponsor":"SQZ Biotechnologies","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Tecentriq (atezolizumab) • Yervoy (ipilimumab) • SQZ-PBMC-HPV"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 01/28/2020","start_date":" 01/28/2020","primary_txt":" Primary completion: 02/09/2023","primary_completion_date":" 02/09/2023","study_txt":" Completion: 02/09/2023","study_completion_date":" 02/09/2023","last_update_posted":"2023-04-14"}]